Clinical Trial

MIBG in Aging and Neurologic Disorders

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09 -> 2027-09 2026-07-31
minor Completion pushed: 2026-09 -> 2027-09 2026-07-31
Trial Details
NCT Number NCT05514106
Lead Sponsor Mayo Clinic
Conditions Lewy Body Disease, Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Enrollment 50 participants
Start Date 2023-05-08
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-30